Advances in the adjuvant and neoadjuvant treatment of breast cancer

Susanne Briest, Vered Stearns

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Several advances in the adjuvant systemic therapy of primary breast cancer have occurred in the last decade and contributed to a decline in disease-related mortality. These include the introduction of aromatase inhibitors, new chemotherapy agents, and the novel antibody trastuzumab. New supportive treatments, such as growth factors, have contributed to the optimization of chemotherapy dose and schedule, and have improved the efficacy and safety of the treatment. In this review we will outline some of the recent advances in the adjuvant and neoadjuvant treatment of breast cancer. We will also discuss ongoing and proposed clinical trials.

Original languageEnglish (US)
Pages (from-to)325-339
Number of pages15
JournalWomen's Health
Issue number3
StatePublished - May 2007


  • Adjuvant treatment
  • Aromatase inhibitors
  • Breast cancer
  • Chemotherapy
  • Hormonal therapy
  • Neoadjuvant treatment
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Advances in the adjuvant and neoadjuvant treatment of breast cancer'. Together they form a unique fingerprint.

Cite this